Catabasis Pharmaceuticals, Inc. Promotes Michael Curtis, Ph.D., to Senior Vice President, Product Development and Regulatory Affairs

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, a biopharmaceutical company leveraging the therapeutic potential of omega-3 fatty acids to create therapeutics for the treatment of inflammatory and metabolic diseases, today announced that Michael Curtis, Ph.D., has been promoted to senior vice president, product development and regulatory affairs. In his new position, Dr. Curtis will be responsible for chemistry, manufacturing and controls functions, toxicology, and regulatory approvals. He will continue to be responsible for leading the company’s product development strategy.